MedTrace Logo

Exercise and Quality of Life During Androgen Deprivation Therapy

NCT04050397 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-09-11

No results posted yet for this study

Summary

This study evaluates effects of supervised exercise in reducing adverse effects of hormonal treatment, increasing quality of life and in inducing a long-term change into more active lifestyle in prostate cancer patients on androgen deprivation therapy. All participants will attend a starting lecture at the beginning of the trial, after which they are randomly allocated to attend 3 months of either supervised or non-supervised exercise program. Leisure time activity, quality of life, blood sugar and cholesterol values, and body composition of participants will be evaluated at three time-points; at recruitment, after 12 weeks and after 24 weeks. Effects on quality of life will also be qualitatively evaluated with single- and group interviews.

Conditions

Interventions

OTHER

Progressive supervised weight training

12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.

OTHER

Lecture

Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.

Sponsors & Collaborators

  • Varalan urheiluopisto

    collaborator UNKNOWN

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Teemu Murtola, MD PhD · Tampereen University, Faculty of Medicine and Health Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-15
Primary Completion
2020-08-15
Completion
2021-08-15

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04050397 on ClinicalTrials.gov